Here's why the Incannex share price is rocketing 18% today

Incannex provided an update on the APIRx takeover.

| More on:
Rising marijuana share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Incannex shares accelerate 17.81% to 43 cents 
  • The company entered into a share sale and purchase agreement to acquire APIRx 
  • Completion of the acquisition is subject to a shareholder vote which will be held at the extraordinary general meeting in June 2022 

The Incannex Healthcare Ltd (ASX: IHL) share price is on the move today following a company's latest acquisition.

At the time of writing, the healthcare company's shares are trading at 43 cents, up 17.81%.

Incannex progresses on APIRx takeover

According to its release, Incannex announced it has entered into a share sale and purchase agreement to acquire APIRx Pharmaceuticals.

Based in the United States, APIRx is a leading pharmaceutical company specialising in cannabinoid active pharmaceutical ingredients and drug products.

The acquisition will be made by an all-scrip transaction of 218 million Incannex shares at a value of $0.573 per share.

This requires Incannex's shareholders to approve the issue of the new shares to the sellers under ASX Listing Rule 7.1.

A shareholder vote will be held at the extraordinary general meeting in June 2022.

If green-lit, the shares will be issued at the completion of the acquisition and thus APIRx will become a wholly-owned subsidiary of the company.

Incannex noted that the acquisition of APIRx delivers a strong portfolio of patented drug candidates. This includes 22 development programs covering a total addressable market of US$400 billion per annum.

Together, Incannex and APIRx will form the world's largest portfolio of patented medicinal cannabinoid drug formulations and psychedelic treatment protocols.

The takeover is expected to be seamless, as APIRx's assets are similar to Incannex's operational capabilities and pharmaceutical development strategy.

Incannex CEO and managing director, Joel Latham commented:

The acquisition of APIRx presents us with clear long and short-term opportunities for significant value growth. Several drug candidates have shortened regulatory pathways to break into areas of patient need representing very large global markets. These candidates are our initial development priority.

Incannex's strong cash position allows us to pursue these near-term product opportunities at the same time as moving at pace to develop the Incannex combination drug candidates. Once the acquisition of APIRx has been finalised, Incannex will have many diverse projects under development, the progress over which we will update the stock exchanges with ongoingly.

Incannex share price snapshot

Over the past 12 months, the Incannex share price has surged close to 60%.

While investor optimism took hold late last year, this hasn't been the case in 2022 with losses sitting around 31%.

The company's shares reached a multi-year high of 75.5 cents in early March, before giving up their astonishing gains.

On valuation grounds, Incannex presides a market capitalisation of around $549.97 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »